Neuroscience Today—July 8, 2026

This week’s Neuroscience update highlights regulatory progress, advancing clinical research, strategic partnerships, digital innovation, and emerging biomarker developments across neurological disorders.

In Today’s Newsletter

Dive deeper

🧬 Itvisma EC approval for SMA [1] [EU • 02 Jul 2026]

https://www.novartis.com/news/media-releases/novartis-receives-european-commission-approval-itvisma-spinal-muscular-atrophy-sma
Context: Approval was based on STEER, STRENGTH, and STRONG data, including a 2.39-point HFMSE improvement sustained over 52 weeks in STEER.
Key point: Novartis said the European Commission approved Itvisma (onasemnogene abeparvovec) for children two years and older, teens, and adults with 5q SMA and bi-allelic SMN1 mutation.
Implication: May influence prescriber choice and payer reviews pending full data.

💤 Cumulus and Muse add at-home sleep EEG for CNS trials [2] [UK/Ireland/Canada • 06 Jul 2026]

https://www.prnewswire.com/news-releases/cumulus-neuroscience-and-muse-by-interaxon-bring-validated-at-home-sleep-eeg-to-cns-clinical-trials-302818229.html
Context: Muse measures sleep architecture at home and reports 88–96% agreement with gold-standard polysomnography, according to the cited Lanthier et al. 2025 study.
Key point: Cumulus Neuroscience and Muse by Interaxon announced integration of Muse at-home sleep EEG into the NeuLogiq platform for CNS clinical trials.
Implication: Could streamline initiation and adherence via remote prescribing and logistics.

🧠 Nona and Lonza partner on BBB-crossing CNS delivery [3] [US • 01 Jul 2026]

https://www.prnewswire.com/news-releases/nona-biosciences-and-lonza-enter-strategic-collaboration-to-develop-best-in-class-single-domain-antibodybased-bbb-crossing-technology-for-cns-diseases-302816472.html
Context: The work uses Nona’s Harbour Mice fully human HCAb platform with Lonza protein development, GS Gene Expression System, and GlycoConnect bioconjugation technology.
Key point: Nona Biosciences and Lonza announced a strategic collaboration to develop single-domain antibody-based BBB-crossing technology for CNS diseases.
Implication: Signals pipeline investment and modality expansion.

🧪 BRIUMVI Phase 2 starts in treatment-resistant schizophrenia [4] [US • 06 Jul 2026]

https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-initiation-phase-2-trial-evaluating
Context: The open-label, single-arm, multicenter study will enroll about 60 adults aged 18–60, with primary endpoint of at least 20% PANSS total score reduction at Week 12.
Key point: TG Therapeutics initiated a Phase 2 trial of BRIUMVI (ublituximab-xiiy) in adults with treatment-resistant schizophrenia.
Implication: May influence prescriber choice and payer reviews pending full data.

💊 Hikma launches XCOPRI in the UAE [5] [UAE • 06 Jul 2026]

https://www.hikma.com/news/hikma-launches-xcopri-cenobamate-tablets-in-the-uae/
Context: Hikma said XCOPRI is the first anti-seizure medicine containing cenobamate launched in the UAE, under its 2023 MENA licensing agreement with SK Biopharmaceuticals.
Key point: Hikma launched XCOPRI (cenobamate tablets) in the UAE for adult patients with partial-onset seizures.
Implication: Introduces competition that may affect pricing and formulary access.

🩸 Blood DNA-RNA model improves Alzheimer’s detection [6] [Korea/US • 06 Jul 2026]

https://www.koreabiomed.com/news/articleView.html?idxno=32315
Context: The analysis included 486 participants from ADNI and SNUBH; the integrated model reached AUC 0.705 versus 0.635 for polygenic risk score alone.
Key point: An SNUBH-led team reported that combining blood-based genomic and transcriptomic risk scores improved Alzheimer’s disease classification versus genetic data alone.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

Why it matters

Gene therapy access in SMA is expanding beyond infants, with Novartis positioning Itvisma for older children, teens, and adults in Europe. [1]
CNS trials are adding lower-burden, home-based digital measures, including sleep EEG, cognition, mood, speech, and wake EEG. [2]
BBB-crossing delivery remains a core bottleneck for CNS drug development, keeping platform partnerships strategically important. [3]
Immunology is moving into psychiatric drug development, with TG Therapeutics testing B-cell depletion in treatment-resistant schizophrenia. [4]
Blood-based multi-omic models may help triage Alzheimer’s risk, but the SNUBH-led study says prospective validation is still needed. [6]

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

📚 View the full Neuroscience archive on our research hub page

🎯 Catch up on the Top Neuroscience news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What is Itvisma, and who is it approved for in Europe?

Itvisma (onasemnogene abeparvovec) is a one-time gene replacement therapy from Novartis. The EC approved it for children two years and older, teens, and adults with 5q SMA and bi-allelic SMN1 mutation. [1]

What does Muse add to Cumulus Neuroscience’s NeuLogiq platform?

Muse adds at-home sleep EEG to NeuLogiq, allowing objective brain-based sleep staging in CNS clinical trials. The source cites 88–96% agreement with polysomnography. [2]

What are Nona Biosciences and Lonza developing?

They are developing single-domain antibody-based BBB-crossing technology for CNS diseases. The collaboration combines Nona’s Harbour Mice HCAb platform with Lonza development and manufacturing capabilities. [3]

What is TG Therapeutics testing with BRIUMVI in schizophrenia?

TG Therapeutics is testing whether B-cell depletion with BRIUMVI can improve symptoms in treatment-resistant schizophrenia. The Phase 2 study is open-label and single-arm, with about 60 adults planned. [4]

What did Hikma launch in the UAE?

Hikma launched XCOPRI (cenobamate tablets) for adult partial-onset seizures. Hikma said it is the first UAE launch of an anti-seizure medicine containing cenobamate. [5]

Is the SNUBH Alzheimer’s blood DNA-RNA model ready for diagnosis?

No. The source says the model improved classification in research cohorts, but it is not ready to replace established diagnostic testing and needs larger prospective studies. [6]

Entities / Keywords

Itvisma: onasemnogene abeparvovec, Novartis, SMA, 5q SMA, SMN1, STEER, STRENGTH, STRONG, HFMSE
Cumulus Neuroscience: NeuLogiq, Muse, Interaxon, at-home sleep EEG, CNS trials, sleep architecture, PSG
Nona Biosciences: Lonza, Harbour Mice, HCAb, VHH binders, BBB-crossing technology, CNS delivery
BRIUMVI: ublituximab-xiiy, TG Therapeutics, B-cell depletion, treatment-resistant schizophrenia, PANSS
XCOPRI: cenobamate tablets, Hikma, SK Biopharmaceuticals, partial-onset seizures, epilepsy, UAE, MENA
SNUBH Alzheimer’s model: genomic risk score, transcriptomic risk score, ADNI, Alzheimer’s disease, AUC, APOE ε4